Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2009 1
2010 2
2011 6
2012 5
2013 11
2014 7
2015 16
2016 29
2017 26
2018 22
2019 24
2020 31
2021 40
2022 25
2023 25
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

213 results

Results by year

Filters applied: . Clear all
Page 1
An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer.
Lindskrog SV, Prip F, Lamy P, Taber A, Groeneveld CS, Birkenkamp-Demtröder K, Jensen JB, Strandgaard T, Nordentoft I, Christensen E, Sokac M, Birkbak NJ, Maretty L, Hermann GG, Petersen AC, Weyerer V, Grimm MO, Horstmann M, Sjödahl G, Höglund M, Steiniche T, Mogensen K, de Reyniès A, Nawroth R, Jordan B, Lin X, Dragicevic D, Ward DG, Goel A, Hurst CD, Raman JD, Warrick JI, Segersten U, Sikic D, van Kessel KEM, Maurer T, Meeks JJ, DeGraff DJ, Bryan RT, Knowles MA, Simic T, Hartmann A, Zwarthoff EC, Malmström PU, Malats N, Real FX, Dyrskjøt L. Lindskrog SV, et al. Among authors: maurer t. Nat Commun. 2021 Apr 16;12(1):2301. doi: 10.1038/s41467-021-22465-w. Nat Commun. 2021. PMID: 33863885 Free PMC article.
Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2).
Seifert R, Emmett L, Rowe SP, Herrmann K, Hadaschik B, Calais J, Giesel FL, Reiter R, Maurer T, Heck M, Gafita A, Morris MJ, Fanti S, Weber WA, Hope TA, Hofman MS, Fendler WP, Eiber M. Seifert R, et al. Among authors: maurer t. Eur Urol. 2023 May;83(5):405-412. doi: 10.1016/j.eururo.2023.02.002. Epub 2023 Mar 17. Eur Urol. 2023. PMID: 36935345 Free article. Review.
Editorial Comment.
Budäus L, Maurer T. Budäus L, et al. Among authors: maurer t. J Urol. 2021 Jun;205(6):1661-1662. doi: 10.1097/JU.0000000000001592.01. Epub 2021 Mar 18. J Urol. 2021. PMID: 33734858 No abstract available.
Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer.
Fanti S, Goffin K, Hadaschik BA, Herrmann K, Maurer T, MacLennan S, Oprea-Lager DE, Oyen WJ, Rouvière O, Mottet N, Bjartell A. Fanti S, et al. Among authors: maurer t. Eur J Nucl Med Mol Imaging. 2021 Feb;48(2):469-476. doi: 10.1007/s00259-020-04934-4. Epub 2020 Jul 2. Eur J Nucl Med Mol Imaging. 2021. PMID: 32617640 Free PMC article.
Prostate-Specific Membrane Antigen-Guided Surgery.
Maurer T, Graefen M, van der Poel H, Hamdy F, Briganti A, Eiber M, Wester HJ, van Leeuwen FWB. Maurer T, et al. J Nucl Med. 2020 Jan;61(1):6-12. doi: 10.2967/jnumed.119.232330. Epub 2019 Nov 15. J Nucl Med. 2020. PMID: 31732677 Free article. Review.
The use of PET/CT in prostate cancer.
Li R, Ravizzini GC, Gorin MA, Maurer T, Eiber M, Cooperberg MR, Alemozzaffar M, Tollefson MK, Delacroix SE, Chapin BF. Li R, et al. Among authors: maurer t. Prostate Cancer Prostatic Dis. 2018 Apr;21(1):4-21. doi: 10.1038/s41391-017-0007-8. Epub 2017 Dec 11. Prostate Cancer Prostatic Dis. 2018. PMID: 29230009 Review.
213 results